T
HE CLINIC IS THE ARM OF THE MMRF PRECISION MEDICINE MODEL that aims to accelerate
clinical trials to rapidly bring new treatments to patients. The Multiple Myeloma Research Consortium
(MMRC), a unique collaborative model of 25 centers in the United States and Canada, evaluates novel
agents and combinations for their safety, efficacy, and feasibility in phase 1 and 2 clinical trials.
2017 Active Clinical Trials
Novel
CB-5083
Relapsed
or R/R
Selinexor/
Kyprolis/
Dex
Sotatercept/
Rev/Dex
Key
Phase 1
Antibodies & Immune
Ibrutinib/
Kyprolis Isatuximab/
Kyprolis
Selinexor/
Dex Atezolizumab
Combinations
Isatuximab
Phase 1/2
PIs & IMIDs
Pomalyst/
Kyprolis/Dex
Pomalyst/
Ninlaro/Dex
Phase 2
Molecularly Targeted
Idasanutlin/
Ninlaro
(Deletion 17p)
Pomalyst/
Ninlaro/
EMD/PCL
PINR
New Dx./
Transplant
SMM
Atezolizumab/Post Transplant
Empliciti/Pomalyst/Velcade/Dex
Ninlaro/
*
Revlimid/
Dex
Transplant
Empliciti/Nivolumab/Dex
Empliciti/Pomalyst/Dex
* This study is currently being conducted at two different sites: Washington University and the University of Chicago.
Question about clinical trials? Please call our Patient Support Center at 1.800.603.6628.
To search for clinical trials, visit MMRFCommunityGateway.org
8
T H E M M R F.ORG